Treatment with 2 monoclonal antibodies completely suppressed HIV for about 40 weeks in patients who participated in a small phase 1 trial. The findings, reported in Nature, suggest that future antibody therapies may offer effective HIV treatment for extended periods without antiretroviral therapy (ART).
